HER-2/neu expression in pancreatic adenocarcinoma: Relation to tumor differentiation and survival

Pancreas

Volumn 14, Issue 3, 1997, Pages 229-236

  Dugan, Michael C ^a,b   Dergham, Sanaa T ^a   Kucway, Roger ^a   Singh, Kanwal ^a   Biernat, Laura ^a   Du, Wei ^a   Vaitkevicius, Vainutis K ^a   Crissman, John D ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Differentiation; Ductal adenocarcinoma; HER 2 neu; Pancreatic cancer; Survival; Tumor grade

Indexed keywords

ONCOPROTEIN;

ARTICLE; CANCER GRADING; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE NEU; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; TUMOR DIFFERENTIATION;

EID: 0030936660     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-199704000-00003     Document Type: Article

References (40)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;65:5-27.
2. Carriaga MT, Henson DE, Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 1995;75:171-90.
3. Aaronson SA. Growth factors and cancer. Science 1994;254:1146-53.
4. Friess H, Yamanaka Y, Kobrin MS, Do DA, Buchler MW, Korc M. Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. Clin Cancer Res 1995;1:1413-20.
5. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein and tyrosine kinase activity. Science 1986;232:1644-6.
6. Bacus SS, Zelnick CR, Plowman G, Yarden Y. Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior. Am J Clin Pathol 1994;102 (Suppl 1):S13-24.
7. Borg A, Tandon AK, Siggurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50:4332-7.
8. Houldsworth J, Cordon-Cardo C, Ladanyi M, Kelsen DP, Chaganti RSK. Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res 1990;50:6417-22.
9. Kameda T, Yasui W, Yoshida K, et al. Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. Cancer Res 1990;50:8002-9.
10. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Kunz J, Beger HG, Korc M. Expression of HER-2/neu oncogene in human pancreatic carcinoma. Hum Pathol 1993;24:1127-34.
11. Hall PA, Hughes CM, Staddon SL, Richman PI, Gullick WJ, Lemoine NR. The c-erbB-2 proto-oncogene in human pancreatic cancer. J Pathol 1990;161:195-200.
12. Sarkar FH, Visscher DW, Crissman JD. Quantitative analysis of HER-2/neu (ERBB2) gene expression using reverse transcriptase polymerase chain reaction. Diagn Mol Pathol 1993;2:210-8.
13. Ratcliffe N, Wells W, Wheeler K, et al. Double staining for c-erbB-2 protein and amplified HER-2/neu in breast carcinomas. Mod Pathol 1996;9:23A (abstract).
14. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-7.
15. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
16. Lee EY, Cibull ML, Strodel WE, Haley JV. Expression of HER-2/neu oncoprotein and epidermal growth factor receptor and prognosis in gastric carcinoma. Arch Pathol Lab Med 1994;118:235-9.
17. Mizutani T, Onda M, Tokunaga A, Yamanaka N, Sugisaki Y. Relationship of c-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 1993;72:2083-8.
18. Falck VG, Gullick WJ. c-erbB-2 oncogene product staining in gastric adenocarcinoma: an immunohistochemical study. J Pathol 1989;159:107-11.
19. Yokota J, Yamamoto T, Miyajima N, et al. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 1988;2:283-7.
20. Lukes AS, Kohler MF, Pieper CF, et al. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 1994;73:2380-5.
21. Berchuck A, Rodriguez G, Kinney RB, et al. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 1991;164:15-21.
22. Kuhn EJ,Kurnot RA, Sesterhenn IA, Chang EH, Moul JW. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol 1993;150:1427-33.
23. Sarkar FH, Grignon DJ, Sakr WA, Tabaczka P, Crissman JD. Over-expression of ERBB2 gene in the prostate of African-American and Caucasian men. Mod Pathol 1996;9:82A.
24. Rachwal WJ, Bongiorno PF, Orringer MB, Whyte RI, Etheier SP, Beer DG. Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinoma. Br J Cancer 1995; 72:56-64.
25. Weidner U, et al. Inverse relationship of epidermal growth factor receptor and HER2/neu gene expression in human renal cell carcinoma. Cancer Res 1990;50:5911-8.
26. Jaskiewicz K, Knge JEJ, Thomson J. Expression of p53 tumor suppressor gene, oncoprotein c-erbB-2, cellular proliferation and differentiation in malignant and benign pancreatic lesions Anticancer Res 1994;14:1919-22.
27. Satoh K, Sasano H, Shimosegawa T, et al. An immunohistochemical study of the c-erbB-2 oncogene product in intraductal mucinhypersecreting neoplasms and in ductal cell carcinomas of the pancreas. Cancer 1993;72:51-6.
28. Carriaga MT, Henson DE. The histologic grading of cancer Cancer 1995;75:406-21.
29. Kloppel G, Lingenthal G, Von Bulow M, Kern HF Histological and fine structural features of pancreatic ductal adenocarcinomas in relation to growth and prognosis: studies in xenografted tumours and clinico-histopathological correlation in a series of 75 cases. Histopathology 1985;9:841-56.
30. Chen J, Baithun SI. Morphological study of 391 cases of exocrine pancreatic tumours with special reference to the classification of exocrine pancreatic carcinoma. J Pathol 1985;146:17-29.
31. Otchiai A, Akimoto S, Kanai Y, Shibata T, Oyama T, Hirohashi S, c-erbB-2 gene product associates with catenins in human cancer cells. Biochem Biophys Res Commun 1994;205:73-8.
32. Johansson B, Bardi G, Pandis N, et al. Karyotypic pattern of pancreatic adenocarcinomas correlates with survival and tumour grade. Int J Cancer 1994;58:8-13.
33. Dugan MC, Dergham ST, Kucway R, et al. HER-2/neu gene expression within intraductal and invasive lesions of the pancreas. Pancreas 1995;11:427 (abstract).
34. DiGiuseppe JA, Day JD, Yeo C, et al. HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Mod Pathol 1996;9:134A (abstract).
35. Somerville JE, Clarke LA, Biggart JD. c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. J Clin Pathol 1992;45:16-20.
36. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotem expression in node-positive breast cancer. Cancer 1994;73: 2359-65.
37. Sarkar FH, Smith MR, Hoover T, et al. c-erbB-2 promoter-specific DNA-bmdmg protein isolated from human breast cancer tissues displays mitogenic activity. J Biol Chem 1994;269:12285-9.
38. Liu Y, el-Ashry D, Chen D, Ding IY, Kern FG. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo Breast Cancer Res Treat 1995;34:97-117.
39. Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10:2435-46.
40. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cell. Oncogene 1994;9:1829-38.